Advertisement

Tumor Biology

, Volume 35, Issue 12, pp 12265–12274 | Cite as

HMGB1 promotes cellular proliferation and invasion, suppresses cellular apoptosis in osteosarcoma

  • Qingbing Meng
  • Jie Zhao
  • Hongbing Liu
  • Guoyou Zhou
  • Wensheng Zhang
  • Xingli Xu
  • Minqian Zheng
Research Article

Abstract

Osteosarcoma is the most common primary malignant bone tumor in children and adolescents. Unfortunately, treatment failures are common due to the metastasis and chemoresistance, but the underlying molecular mechanism remains unclear. Accumulating evidence indicated that the deregulation of DNA-binding protein high-mobility group box 1 (HMGB1) was associated with the development of cancer. This study aimed to explore the expression of HMGB1 in osteosarcoma tissues and its correlation to the clinical pathology of osteosarcoma and to discuss the role of HMGB1 in the development of osteosarcoma. The results from RT-PCR and Western blot showed that the expression rate of HMGB1 messenger RNA (mRNA) and the expression of HMGB1 in the osteosarcoma tissues were significantly higher than those in normal bone tissue (p < 0.05), the expression rate of HMGB1 mRNA and the expression of HMGB1 in the carcinoma tissues with positive lung metastasis were significantly higher than those without lung metastasis (p < 0.05), and with increasing Enneking stage, the expression rate of HMGB1 mRNA and the expression of HMGB1 also increased (p < 0.05). In order to explore the role of HMGB1 in osteosarcoma, the expression of HMGB1 in the human osteosarcoma MG-63 cell line was downregulated by the technique of RNA interference. Western blot results showed that the protein expression of HMGB1 was significantly decreased in the MG-63 cells from HMGB1-siRNA transfection group (p < 0.05), which suggested that HMGB1 was successfully downregulated in the MG-63 cells. Then the changes in proliferation, apoptosis, and invasion of MG-63 cells were examined by MTT test, PI staining, annexin V staining, and transwell chamber assay. Results showed that the abilities of proliferation and invasion were suppressed in HMGB1 knockdown MG-63 cells, and the abilities of apoptosis were enhanced in HMGB1 knockdown MG-63 cells. The expression of cyclin D1, MMP-9 was downregulated in HMGB1 knockdown MG-63 cells, and the expression of caspase-3 was upregulated in HMGB1 knockdown MG-63 cells. Taken together, the overexpression of HMGB1 in osteosarcoma might be related to the tumorigenesis, invasion, and metastasis of osteosarcoma, which might be a potential target for the treatment of osteosarcoma.

Keywords

HMGB1 Osteosarcoma RNA interference 

Notes

Acknowledgments

This study was supported by National Natural Science Foundation of China (No. 81402226).

Conflicts of interest

None

References

  1. 1.
    Li R, Liu J, Wu H, Liu L, Wang L, Zhang S. TIKI2 suppresses growth of osteosarcoma by targeting Wnt/β-catenin pathway. Mol Cell Biochem. 2014;392:109–16.PubMedCrossRefGoogle Scholar
  2. 2.
    PosthumaDeBoer J, Witlox MA, Kaspers GJ, van Royen BJ. Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature. Clin Exp Metastasis. 2011;28:493–503.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Bielack SS, Carrle D, Hardes J, Schuck A, Paulussen M. Bone tumors in adolescents and young adults. Curr Treat Options Oncol. 2008;9:67–80.PubMedCrossRefGoogle Scholar
  4. 4.
    Mirabello L, Troisi RJ, Savage SA. International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer. 2009;125:229–34.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the surveillance, epidemiology, and end results program. Cancer. 2009;115:1531–43.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    He H, Ni J, Huang J. Molecular mechanisms of chemoresistance in osteosarcoma (review). Oncol Lett. 2014;7:1352–62.PubMedCentralPubMedGoogle Scholar
  7. 7.
    Chiappetta C, Leopizzi M, Censi F, Puggioni C, Petrozza V, Rocca CD, et al. Correlation of the Rac1/Rhoa pathway with ezrin expression in osteosarcoma. Appl Immunohistochem Mol Morphol. 2014;22:162–70.PubMedCrossRefGoogle Scholar
  8. 8.
    Hou CH, Lin FL, Tong KB, Hou SM, Liu JF. Transforming growth factor alpha promotes osteosarcoma metastasis by ICAM-1 and PI3K/Akt signaling pathway. Biochem Pharmacol. 2014;89:453–63.PubMedCrossRefGoogle Scholar
  9. 9.
    Shen A, Zhang Y, Yang H, Xu R, Huang G. Overexpression of ZEB1 relates to metastasis and invasion in osteosarcoma. J Surg Oncol. 2012;105:830–4.PubMedCrossRefGoogle Scholar
  10. 10.
    Tumbar T, Guasch G, Greco V, Blanpain C, Lowry WE, Rendl M, et al. Defining the epithelial stem cell niche in skin. Science. 2004;303:359–63.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Spradling A, Drummond-Barbosa D, Kai T. Stem cells find their niche. Nature. 2001;414:98–104.PubMedCrossRefGoogle Scholar
  12. 12.
    Hu YH, Yang L, Zhang CG. HMGB1-a as potential target for therapy of hematological malignancies. Zhongguo shi yan xue ye xue za zhi. 2014;22:560–4.PubMedGoogle Scholar
  13. 13.
    Srinivasan M, Banerjee S, Palmer A, Zheng G, Chen A, Bosland MC, et al. HMGB1 in hormone-related cancer: a potential therapeutic target. Horm Cancer. 2014;5:127–39.PubMedCrossRefGoogle Scholar
  14. 14.
    Yildirim M, Suren D, Demirpence O, Kaya V, Alikanoglu AS, Bulbuller N, et al. The role of high mobility group box 1 (HMGB1) in colorectal cancer. Med Sci Monit. 2014;20:530–7.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Xiao J, Ding Y, Huang J, Li Q, Liu Y, Ni W, et al. The association of HMGB1 gene with the prognosis of HCC. PLoS ONE. 2014;9:e89097.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Liu K, Huang J, Xie M, Yu Y, Zhu S, Kang R, et al. MIR34a regulates autophagy and apoptosis by targeting HMGB1 in the retinoblastoma cell. Autophagy. 2014;10:442–52.PubMedCrossRefGoogle Scholar
  17. 17.
    Jia L, Clear A, Liu FT, Matthews J, Uddin N, McCarthy A, et al. Extracellular HMGB1 promotes differentiation of nurse-like cells in chronic lymphocytic leukemia. Blood. 2014;123:1709–19.PubMedCrossRefGoogle Scholar
  18. 18.
    Weng H, Deng Y, Xie Y, Liu H, Gong F. Expression and significance of HMGB1, TLR4 and NF-κB p65 in human epidermal tumors. BMC Cancer. 2013;13:311.PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Moser B, Janik S, Schiefer AI, Mullauer L, Bekos C, Scharrer A, et al. Expression of rage and HMGB1 in thymic epithelial tumors, thymic hyperplasia and regular thymic morphology. PLoS ONE. 2014;9:e94118.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Zhang J, Kou YB, Zhu JS, Chen WX, Li S. Knockdown of HMGB1 inhibits growth and invasion of gastric cancer cells through the NF-κB pathway in vitro and in vivo. Int J Oncol. 2014;44:1268–76.PubMedGoogle Scholar
  21. 21.
    Srinivasan M, Banerjee S, Palmer A, Zheng G, Chen A, Bosland MC, et al. HMGB1 in hormone-related cancer: a potential therapeutic target. Horm Cancer. 2014;5(3):127–39.Google Scholar
  22. 22.
    Dong YD, Cui L, Peng CH, Cheng DF, Han BS, Huang F. Expression and clinical significance of HMGB1 in human liver cancer: knockdown inhibits tumor growth and metastasis in vitro and in vivo. Oncol Rep. 2013;29:87–94.PubMedGoogle Scholar
  23. 23.
    Liu Y, Xie CL, Qiu YZ, Tian YQ, Zhang X, Huang DH, et al. Expression of HMGB1 protein in laryngeal squamous cell carcinoma and its clinical significance. Zhonghua zhong liu za zhi. 2012;34:132–6.PubMedGoogle Scholar
  24. 24.
    Ko YB, Kim BR, Nam SL, Yang JB, Park SY, Rho SB. High-mobility group box 1 (HMGB1) protein regulates tumor-associated cell migration through the interaction with BTB domain. Cell Signal. 2014;26:777–83.PubMedCrossRefGoogle Scholar
  25. 25.
    Chen J, Xi B, Zhao Y, Yu Y, Zhang J, Wang C. High-mobility group protein B1 (HMGB1) is a novel biomarker for human ovarian cancer. Gynecol Oncol. 2012;126:109–17.PubMedCrossRefGoogle Scholar
  26. 26.
    Chen J, Liu X, Zhang J, Zhao Y. Targeting HMGB1 inhibits ovarian cancer growth and metastasis by lentivirus-mediated RNA interference. J Cell Physiol. 2012;227:3629–38.PubMedCrossRefGoogle Scholar
  27. 27.
    Yu Y, Xie M, Kang R, Livesey KM, Cao L, Tang D. HMGB1 is a therapeutic target for leukemia. Am J Blood Res. 2012;2:36–43.PubMedCentralPubMedGoogle Scholar
  28. 28.
    Monga SP. Role and regulation of β-catenin signaling during physiological liver growth. Gene Expr. 2014;16:51–62.PubMedCrossRefGoogle Scholar
  29. 29.
    Mazumder S, Plesca D, Almasan A. Caspase-3 activation is a critical determinant of genotoxic stress-induced apoptosis. Methods Mol Biol. 2008;414:13–21.PubMedGoogle Scholar
  30. 30.
    Xu YB, Du QH, Zhang MY, Yun P, He CY. Propofol suppresses proliferation, invasion and angiogenesis by down-regulating ERK-VEGF/MMP-9 signaling in Eca-109 esophageal squamous cell carcinoma cells. Eur Rev Med Pharmacol Sci. 2013;17:2486–94.PubMedGoogle Scholar
  31. 31.
    Cock-Rada AM, Medjkane S, Janski N, Yousfi N, Perichon M, Chaussepied M, et al. SMYD3 promotes cancer invasion by epigenetic upregulation of the metalloproteinase MMP-9. Cancer Res. 2012;72:810–20.PubMedCentralPubMedCrossRefGoogle Scholar
  32. 32.
    Zwaga T, Bovee JV, Kroon HM. Osteosarcoma of the femur with skip, lymph node, and lung metastases. Radiographics. 2008;28:277–83.PubMedCrossRefGoogle Scholar
  33. 33.
    Gatla HR, Singha B, Persaud V, Vancurova I. Evaluating cytoplasmic and nuclear levels of inflammatory cytokines in cancer cells by Western blotting. Methods Mol Biol. 2014;1172:271–83.PubMedCrossRefGoogle Scholar
  34. 34.
    Zhang P, Liu Y, Wu ZH, Chen J, Chen G, Zhou QH. Effects of high mobility group box-1 silencing upon the invasion and proliferation in human lung cancer cell L9981 by RNA inhibition. Zhonghua yi xue za zhi. 2009;89:3156–9.PubMedGoogle Scholar
  35. 35.
    Yin Y, Li W, Deng M, Zhang P, Shen Q, Wang G, et al. Extracellular high mobility group box chromosomal protein 1 promotes drug resistance by increasing the expression of P-glycoprotein expression in gastric adenocarcinoma cells. Mol Med Rep. 2014;9:1439–43.PubMedGoogle Scholar
  36. 36.
    Song B, Song WG, Li ZJ, Xu ZF, Wang XW, Wang CX, et al. Effect of HMGB1 silencing on cell proliferation, invasion and apoptosis of MGC-803 gastric cancer cells. Cell Biochem Funct. 2011. doi:  10.1002/cbf.1811.
  37. 37.
    Gnanasekar M, Thirugnanam S, Ramaswamy K. Short hairpin RNA (shRNA) constructs targeting high mobility group box-1 (HMBG1) expression leads to inhibition of prostate cancer cell survival and apoptosis. Int J Oncol. 2009;34:425–31.PubMedGoogle Scholar
  38. 38.
    Yu Y, Xie M, He YL, Xu WQ, Zhu S, Cao LZ. Role of high mobility group box 1 in adriamycin-induced apoptosis in leukemia K562 cells. Ai zheng. 2008;27:929–33.PubMedGoogle Scholar
  39. 39.
    Suren D, Yildirim M, Demirpence O, Kaya V, Alikanoglu AS, Bulbuller N, et al. The role of high mobility group box 1 (HMGB1) in colorectal cancer. Med Sci Monit. 2014;20:530–7.PubMedCentralPubMedCrossRefGoogle Scholar
  40. 40.
    Chen RC, Yi PP, Zhou RR, Xiao MF, Huang ZB, Tang DL, et al. The role of HMGB1-rage axis in migration and invasion of hepatocellular carcinoma cell lines. Mol Cell Biochem. 2014;390:271–80.PubMedCentralPubMedCrossRefGoogle Scholar
  41. 41.
    Li ZJ, Song B, Liu J, Han JJ, Wang CX, Zhu YX, et al. Inhibitory effect of silencing of HMGB1 gene expression on the invasive and metastatic abilities of MGC-803 gastric cancer cells. Zhonghua zhong liu za zhi. 2013;35:244–8.PubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Qingbing Meng
    • 1
  • Jie Zhao
    • 2
  • Hongbing Liu
    • 1
  • Guoyou Zhou
    • 1
  • Wensheng Zhang
    • 1
  • Xingli Xu
    • 1
  • Minqian Zheng
    • 1
  1. 1.Orthopedics DepartmentYancheng City No.1 People’s HospitalYanchengPeople’s Republic of China
  2. 2.Orthopedics DepartmentShanghai Ninth People’s Hospital Affiliated to Shanghai Jiao Tong University School of MedicineShanghaiPeople’s Republic of China

Personalised recommendations